We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CUBICIN (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
CUBICIN
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
daptomycin
Registration type
EOI
Indication
CUBICIN (powder for injection) is now also indicated for:
Staphylococcus aureus Bloodstream Infections (Bacteraemia)
CUBICIN is indicated in paediatric patients (1 to 17 years of age) with Staphylococcus aureus bacteraemia not due to pneumonia, caused by daptomycin-susceptible isolates. Empiric treatment should be reviewed based on the results of susceptibility testing. Prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of Staphylococcus aureus bacteraemia.